Early Radiographic Progression of Scleroderma

[1]  J. Goldin,et al.  Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2020, The Lancet. Respiratory medicine.

[2]  M. Roth,et al.  Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II , 2020, ACR open rheumatology.

[3]  G. Sergiacomi,et al.  Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters? , 2020, Respiratory Research.

[4]  R. Elashoff,et al.  Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts , 2018, Annals of the rheumatic diseases.

[5]  M. Boubaya,et al.  Mapping and predicting mortality from systemic sclerosis , 2017, Annals of the rheumatic diseases.

[6]  A. Nicholson,et al.  Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis , 2017, Arthritis & rheumatology.

[7]  Raúl San José Estépar,et al.  Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. , 2016, American journal of respiratory and critical care medicine.

[8]  R. Elashoff,et al.  Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial , 2016, The Lancet. Respiratory medicine.

[9]  R. D. du Bois,et al.  Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis , 2016, Thorax.

[10]  R. Elashoff,et al.  Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment , 2016, Annals of the rheumatic diseases.

[11]  R. Elashoff,et al.  Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis , 2014, Annals of the rheumatic diseases.

[12]  M. Roth,et al.  Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials , 2015, Arthritis Research & Therapy.

[13]  Kyle J Myers,et al.  Quantitative imaging biomarkers: A review of statistical methods for computer algorithm comparisons , 2014, Statistical methods in medical research.

[14]  Sumit K. Shah,et al.  Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide , 2011, European Radiology.

[15]  Chi-Hong Tseng,et al.  Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. , 2011, Arthritis and rheumatism.

[16]  M S Brown,et al.  A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. , 2010, Clinical and experimental rheumatology.

[17]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[18]  Xiaohong Yan,et al.  Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. , 2007, Arthritis and rheumatism.

[19]  Stefano Diciotti,et al.  Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. , 2007, Chest.

[20]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.